Literature DB >> 9323343

Performance on tests sensitive to impaired executive ability in schizophrenia, mania and well controls: acute and subacute phases.

J McGrath1, S Scheldt, J Welham, A Clair.   

Abstract

AIMS: To compare the performance of schizophrenia, mania and well control groups on tests sensitive to impaired executive ability, and to assess the within-group stability of these measures across the acute and subacute phases of psychoses.
METHOD: Recently admitted patients with schizophrenia (n = 36), mania (n = 18) and a well control group (n = 20) were assessed on two occasions separated by 4 weeks. Tests included: the Controlled Oral Word Association Test, the Stroop Test, the Wisconsin Card Sort Test, and the Trail Making Test.
RESULTS: The two patient groups were significantly impaired on the Stroop Test at both time points compared to the control group. Significant group differences were also found for the Trail Making Test at Time 1 and for the Wisconsin Card Sort Test at Time 2. When controlled for practice effect, significant improvements over time were found on the Stroop and Trail Making tests in schizophrenia group and on WCST Categories Achieved in the mania group. DISCUSSION: Compared to controls, the patient groups were impaired on measures related to executive ability. The pattern of improvement on test scores between the acute and subacute phases differed between patients with schizophrenia versus patients with mania.

Entities:  

Mesh:

Year:  1997        PMID: 9323343     DOI: 10.1016/s0920-9964(97)00070-4

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  27 in total

1.  Acute effects of cocaine on the neurobiology of cognitive control.

Authors:  Hugh Garavan; Jacqueline N Kaufman; Robert Hester
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-10-12       Impact factor: 6.237

2.  Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients.

Authors:  E Fakra; S Khalfa; D Da Fonseca; N Besnier; P Delaveau; J M Azorin; O Blin
Journal:  Psychopharmacology (Berl)       Date:  2008-06-25       Impact factor: 4.530

Review 3.  Specifying the neuropsychology of affective disorders: clinical, demographic and neurobiological factors.

Authors:  Thomas Beblo; Grant Sinnamon; Bernhard T Baune
Journal:  Neuropsychol Rev       Date:  2011-06-10       Impact factor: 7.444

4.  Cognitive deficits in bipolar disorder: from acute episode to remission.

Authors:  J Volkert; M A Schiele; Julia Kazmaier; Friederike Glaser; K C Zierhut; J Kopf; S Kittel-Schneider; A Reif
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-26       Impact factor: 5.270

5.  A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state.

Authors:  Matthew M Kurtz; Raphael T Gerraty
Journal:  Neuropsychology       Date:  2009-09       Impact factor: 3.295

6.  Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory.

Authors:  Rebekah A E Honey; Danielle C Turner; Garry D Honey; Sam R Sharar; D Kumaran; E Pomarol-Clotet; P McKenna; B J Sahakian; T W Robbins; P C Fletcher
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

Review 7.  Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy.

Authors:  Katherine E Burdick; Raphael J Braga; Joseph F Goldberg; Anil K Malhotra
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 8.  Neurocognitive allied phenotypes for schizophrenia and bipolar disorder.

Authors:  S Kristian Hill; Margret S H Harris; Ellen S Herbener; Mani Pavuluri; John A Sweeney
Journal:  Schizophr Bull       Date:  2008-04-29       Impact factor: 9.306

9.  Differential executive functioning performance by phase of bipolar disorder.

Authors:  Kelly A Ryan; Aaron C Vederman; E Michelle McFadden; Anne L Weldon; Masoud Kamali; Scott A Langenecker; Melvin G McInnis
Journal:  Bipolar Disord       Date:  2012-08       Impact factor: 6.744

10.  Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER.

Authors:  Michael Birnbaum; Zafar Sharif
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.